Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2000
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic drugs for serious medical conditions. As of the reporting date, the company had not generated any sales or profits from the commercialization of its own product candidates. Revenue is derived from research collaborations, contract manufacturing, and investment income.
Key Financial Metrics
| Metric (in thousands) | 2000 | 1999 |
|---|---|---|
| Total Revenues | $59,276 | $34,499 |
| Net Loss | $(23,215) | $(23,070) |
| Net Loss Per Share (Basic & Diluted) | $(0.66) | $(0.74) |
| Cash, Cash Equivalents, and Marketable Securities | $154,370 | $93,599 |
| Total Assets | $208,274 | $136,999 |
| Stockholders' Equity | $182,130 | $109,532 |
| Long-Term Debt (Capital Leases & Notes) | $2,069 | $2,731 |
Revenue Breakdown (2000):
- Contract Research and Development: $36.5 million
- Contract Manufacturing: $16.6 million
- Research Progress Payments: $6.2 million
Expense Breakdown (2000):
- Research and Development: $56.3 million (67% of total operating expenses)
- Contract Manufacturing: $15.6 million
- General and Administrative: $8.3 million
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 72% to $59.3 million in 2000 from $34.5 million in 1999. This was driven by a 49% increase in contract research revenue (largely from Procter & Gamble) and a 66% increase in contract manufacturing revenue (primarily from Merck).
- Operating Expenses: Total operating expenses rose 45% to $84.6 million, primarily due to increased R&D staffing and activity, and higher contract manufacturing costs associated with initiating commercial production for Merck.
- Investment Income: Increased to $8.5 million from $5.2 million due to interest earned on proceeds from a public offering in April 2000 and a stock sale to Procter & Gamble in August 2000.
- Accounting Change: The company adopted Staff Accounting Bulletin 101 (SAB 101) effective January 1, 2000, resulting in a cumulative effect adjustment that increased the net loss by $1.6 million.
Guidance, Outlook, and Risks
Outlook and Capital Resources:
- Management believes existing capital resources ($154.4 million in cash and securities) will fund operations through the third quarter of 2002.
- For 2001-2002, approximately 50-70% of expenditures are expected to be directed toward preclinical and clinical development of product candidates (AXOKINE, IL-1 Trap, VEGF Trap, etc.).
- A proposed public offering of 4.0 million shares was filed in January 2001 to secure additional funding.
Key Clinical Developments:
- AXOKINE (Obesity): Phase II results showed statistically significant weight loss. Phase III testing is planned for mid-2001.
- IL-1 Trap (Rheumatoid Arthritis): Phase I study initiated in December 2000.
- BDNF (ALS): In January 2001, the Amgen-Regeneron partnership discontinued BDNF development for ALS after clinical trials showed no therapeutic advantage.
Risks and Contingencies:
- Patent Litigation: Immunex Corporation filed an opposition in September 2000 challenging the scope of Regeneron's European patent for Cytokine Traps.
- Collaboration Dependency: Revenue relies heavily on collaborations with Procter & Gamble, Amgen, and Sumitomo. Termination of these agreements could materially impact operations.
- Regulatory Approval: No products have been approved for commercial sale; future success depends on FDA and foreign regulatory approvals.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $154.4 million cash balance to fund the planned Phase III trials for AXOKINE and other pipeline candidates through 2002 without further dilution.
- Collaboration Terms: Review the specific terms of the new Procter & Gamble agreement (effective 2001) regarding the reduction in quarterly research support from $6.8 million to $2.5 million.
- BDNF Impact: Assess the financial impact of the discontinued BDNF program on the Amgen-Regeneron partnership and future revenue from Sumitomo Pharmaceuticals.
- Patent Status: Monitor the outcome of the Immunex opposition regarding the Cytokine Trap patent, which is central to the IL-1 Trap and IL-4/IL-13 Trap programs.
- Contract Manufacturing: Confirm the stability of the Merck manufacturing agreement, which provides a significant portion of current revenue and covers facility costs.